Activating mutations in the NF‐κB pathway are also known to drive MM.44 OTS514 treatment caused a marked decrease in the phosphorylated form of IκBα in four of the five HMCLs examined, indicating that TOPK inhibition also suppresses the canonical NF‐κB pathway and its MM‐supportive targets. This evidence concerns the gene NFKB1 and Miyoshi myopathy.